Our further study determined that the benefits of miR-122-5p inhibitor in obese mice could be abolished by silencing FOXO3, including decreasing lipid accumulation, which also demonstrated that miR-122-5p targeting on FOXO3 played a crucial role in obesity-induced mouse fatty liver diseases. This evidence concerns the gene FOXO3 and fatty liver disease.